Searchable abstracts of presentations at key conferences in endocrinology

ea0035p770 | Obesity | ECE2014

GLP1 analogs as treatment of postprandial hypoglycemia after gastric bypass for morbid obesity

Abrahamsson Niclas , Engstrom Britt Eden , Sundbom Magnus , Karlsson Anders

Introduction: In a fraction of morbidly obese subjects undergoing gastric bypass (GBP), episodes with late postprandial hypoglycemia (PPHG) develop 1–3 years after surgery. The pathogenesis of this phenomenon is not fully understood; meal-induced rapid and exaggerated increases of circulating incretins and insulin appear to be partially responsible. Current treatments include low-carbohydrate diets, inhibition of glucose intestinal uptake, reduction of insulin secretion w...

ea0081ep157 | Calcium and Bone | ECE2022

Vitamin D and bone metabolism in Graves’ disease. A prospective study

Khamisi Selwan , Lundquist Martin , Rasmusson Annica , Engstrom Britt Eden , Karlsson F Anders , Ljunggren Osten

Objective: Vitamin D and osteoporosis in Graves’ disease (GD) have previously been examined in cross-sectional studies with partly divergent results. Here, we prospectively studied vitamin D metabolism and bone health in patients with newly diagnosed GD.Methods: Thirty consecutive patients with de novo overt thyrotoxicosis diagnosed with GD were included. None of the patients at diagnosis were treated with vitamin D supplementation or anti ...

ea0020p205 | Endocrine tumours and neoplasia | ECE2009

Acromegaly in the Swedish pituitary register: background data and up to 10 years follow-up

Engstrom Britt Eden , Bramnert Margareta , Ekman Bertil , Hoybye Charlotte , Karlsson Anders , Mattsson Cecilia , Rosen Thord , Valdemarsson Stig , Werner Sigbritt

Background: The aim of the Swedish Pituitary Register – the Swedish Pituitary Study Group’s quality register – is to guarantee that all patients with pituitary tumours get equivalent diagnostic evaluation and treatment, as well as to evaluate given therapy. In this study, patients diagnosed with acromegaly from 1991 are described.Methods: Data from 557 patients (275 men/282 women), median age 51 years (range 4–87), with acromegaly wer...

ea0056gp29 | Adrenal clinical | ECE2018

Salivary cortisol and cortisone in Cushing diagnosis – reference ranges and clinical cut off limits

Backlund Nils , Brattsand Goran , Israelsson Marlen , Ragnarsson Oskar , Burman Pia , Engstrom Britt Eden , Hoybye Charlotte , Berinder Katarina , Wahlberg Jeanette , Dahlqvist Per

Introduction: Cushing’s syndrome is rare, but assessment of patients with clinical suspicion of Cushing’s and/or adrenal incidentaloma is frequently required. Thus, there is a need for biochemical screening methods that with high sensitivity and specificity identifies or rule out hypercortisolism. Analysis of late night salivary cortisol allows an easy sampling procedure performed at home and is independent of variations in plasma CBG levels. Analysis by liquid chrom...

ea0041gp167 | Pituitary - Clinical (1) | ECE2016

Sleep apnea in patients with acromegaly – prevalence, diagnosis and risk factors

Vouzouneraki Konstantina , Franklin Karl , Forsgren Maria , Warn Maria , Tiberg Jenny , Wik Helena , Dahlgren Christina , Alkebro Caroline , Nilsson Ann-Sofie , AEkerman Anna-Karin , Burman Pia , Hoybye Charlotte , Ragnarsson Oskar , Wahlberg Jeanette , Engstrom Britt Eden , Dahlqvist Per

Introduction: Patients with acromegaly have an increased mortality, mainly due to cardiovascular and respiratory diseases. Sleep apnea is related to hypertension, stroke and cardiovascular diseases and is reported to occur in 11–30% of acromegaly patients, according to retrospective studies based on diagnostic ICD-codes. However, in smaller prospective studies sleep apnea is found in about 70% of patients with active acromegaly and 40% after biochemical control. This diff...

ea0056gp30 | Adrenal clinical | ECE2018

The urinary cortisol metabolome in patients with adrenal insufficiency: dual-release hydrocortisone is less deleterious than conventional hydrocortisone therapy

Espiard Stephanie , McQueen Johanna , Sherlock Mark , Ragnarsson Oskar , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Engstrom Britt Eden , Nilsson Anna G , Skrtic Stanko , Wahlberg Jeanette , Stewart Paul M , Johannsson Gudmundur

Introduction: Oral once-daily dual-release hydrocortisone (DR-HC) therapy provides a more physiological cortisol profile than conventional thrice-daily (TID) replacement therapy and has demonstrated improved metabolic profile among patients with adrenal insufficiency (AI). The mechanisms by which this metabolic improvement occurs may be due to less total exposure, changed cortisol time exposure profile, but also modified metabolism of cortisol.Objective:...

ea0049gp9 | Adrenal 1 | ECE2017

Mortality is increased in patients with Cushing’s disease in long-term remission: A nation-wide study

Chantzichristos Dimitrios , Papakokkinou Eleni , Dahlqvist Per , Segerstedt Elin , Olsson Tommy , Berinder Katarina , Hoybye Charlotte , Bensing Sophie , Engstrom Britt Eden , Burman Pia , Folin Cecilia , Erfurth Eva Marie , Wahlberg Jeanette , Ekman Bertil , Schwarcz Erik , Bryngelsson Ing-Liss , Andersson Eva , Johannsson Gudmundur , Olsson Daniel S , Ragnarsson Oskar

Background: It is still undetermined whether patients with Cushing’s disease (CD) in remission have an increased mortality. Most previous studies are limited by small numbers of patients and/or short follow-up time.Objective: To study mortality in a nation-wide cohort of patients with CD during long-term follow-up.Methods: Patients with ICD codes for Cushing’s syndrome and/or CD, between 1987 and 2013, were identified in ...